Revenio Group Oyj (REG1V) Stock Overview
Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for REG1V from our risk checks.
REG1V Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Revenio Group Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €12.52 |
| 52 Week High | €29.10 |
| 52 Week Low | €12.34 |
| Beta | 0.84 |
| 1 Month Change | -11.08% |
| 3 Month Change | -31.13% |
| 1 Year Change | -54.06% |
| 3 Year Change | -61.24% |
| 5 Year Change | -79.56% |
| Change since IPO | 558.96% |
Recent News & Updates
Narrative Update • Jun 16
REG1V: Street Downgrades Will Set Up Future Upside Repricing
Analysts maintained their fair value estimate for Revenio Group Oyj at €18.0. A slightly lower discount rate and a marginally reduced future P/E assumption reflect more cautious sentiment following recent downgrades in Street research. Analyst Commentary on Revenio Group Oyj Recent Street research on Revenio Group Oyj has turned more cautious, with multiple downgrades pointing to concerns that contrast with the fair value estimate being held at €18.0. For you as an investor, the key is to distinguish where analysts still see support for the valuation from where they see growing execution and growth risks.Narrative Update • Jun 02
REG1V: Acquisition And Dividend Pause Will Support Future Upside Repricing
Analysts have slightly reduced their 12‑month price target for Revenio Group Oyj, setting fair value at €18.0. This reflects more cautious views following recent downgrades, while key model inputs such as the discount rate and future P/E assumptions remain broadly similar. Analyst Commentary Bullish Takeaways Bullish analysts still see support for the current valuation framework, with core assumptions around the discount rate and future P/E remaining intact despite the latest target revision to €18.0. There is a view that, if execution on existing plans stays on track, the current fair value could reflect a reasonable balance between growth potential and risk without relying on aggressive upgrades.
New Narrative • May 25
Visionix Acquisition And AI Screening Will Reshape Long Term Ophthalmic Diagnostics Potential
Catalysts About Revenio Group Oyj Revenio Group Oyj focuses on ophthalmic diagnostic devices and related software used across eye care settings. What are the underlying business or industry changes driving this perspective?Narrative Update • May 18
REG1V: Acquisition Driven Dividend Pause Will Support Future Upside Repricing
Analysts have trimmed their fair value estimate for Revenio Group Oyj from €19.38 to €18.00, reflecting slightly lower assumptions for revenue growth and future P/E multiples. This was partly offset by a small uplift in projected profit margins and a modest reduction in the discount rate, alongside recent price target cuts and downgrades from several brokers.Recent updates
Narrative Update • Jun 16
REG1V: Street Downgrades Will Set Up Future Upside Repricing
Analysts maintained their fair value estimate for Revenio Group Oyj at €18.0. A slightly lower discount rate and a marginally reduced future P/E assumption reflect more cautious sentiment following recent downgrades in Street research. Analyst Commentary on Revenio Group Oyj Recent Street research on Revenio Group Oyj has turned more cautious, with multiple downgrades pointing to concerns that contrast with the fair value estimate being held at €18.0. For you as an investor, the key is to distinguish where analysts still see support for the valuation from where they see growing execution and growth risks.Narrative Update • Jun 02
REG1V: Acquisition And Dividend Pause Will Support Future Upside Repricing
Analysts have slightly reduced their 12‑month price target for Revenio Group Oyj, setting fair value at €18.0. This reflects more cautious views following recent downgrades, while key model inputs such as the discount rate and future P/E assumptions remain broadly similar. Analyst Commentary Bullish Takeaways Bullish analysts still see support for the current valuation framework, with core assumptions around the discount rate and future P/E remaining intact despite the latest target revision to €18.0. There is a view that, if execution on existing plans stays on track, the current fair value could reflect a reasonable balance between growth potential and risk without relying on aggressive upgrades.New Narrative • May 25
Visionix Acquisition And AI Screening Will Reshape Long Term Ophthalmic Diagnostics Potential
Catalysts About Revenio Group Oyj Revenio Group Oyj focuses on ophthalmic diagnostic devices and related software used across eye care settings. What are the underlying business or industry changes driving this perspective?Narrative Update • May 18
REG1V: Acquisition Driven Dividend Pause Will Support Future Upside Repricing
Analysts have trimmed their fair value estimate for Revenio Group Oyj from €19.38 to €18.00, reflecting slightly lower assumptions for revenue growth and future P/E multiples. This was partly offset by a small uplift in projected profit margins and a modest reduction in the discount rate, alongside recent price target cuts and downgrades from several brokers.Narrative Update • May 03
REG1V: Dividend Pause And Acquisition Integration Will Support Future Upside Repricing
Analysts have trimmed their price target on Revenio Group Oyj to €19.38 from €23.33, reflecting recent downgrades and a recalibration of fair value, discount rate, growth, profitability, and future P/E assumptions in light of mixed Street research. Analyst Commentary Recent Street research on Revenio Group Oyj has shifted in a mixed direction, with both upgrades and downgrades clustered over a relatively short period.
New Narrative • May 03
Ophthalmic Expansion And Visionix Integration Will Shape Balanced Long Term Prospects
Catalysts About Revenio Group Oyj Revenio Group Oyj focuses on ophthalmic diagnostic devices and related software, with a growing presence in fundus imaging, tonometry and eye screening solutions. What are the underlying business or industry changes driving this perspective?Narrative Update • Apr 19
REG1V: Dividend Pause For Acquisition Funding Will Support Future Upside Repricing
Narrative Update on Revenio Group Oyj The updated analyst price target for Revenio Group Oyj moves slightly higher to about €23.33 from €23.06, as analysts factor in recent target revisions around €23.50 along with refreshed assumptions for discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent research suggests a mixed but generally constructive stance on Revenio Group Oyj, with some analysts adjusting their price targets while others have moved to more optimistic ratings on the shares.Narrative Update • Apr 05
REG1V: Dividend Flexibility And Fresh Upgrades Will Support Future Upside Repricing
Revenio Group Oyj's updated analyst price target edges down to €23.06, with analysts citing slightly higher discount rate assumptions, a modestly adjusted fair value of €23.06 versus €23.55, and recent mixed Street research, including a reduced €23.50 target alongside fresh upgrades, as key inputs to their latest view. Analyst Commentary Recent Street research around Revenio Group Oyj is mixed but generally constructive, with some analysts getting more positive on the shares while others trim valuation assumptions.Narrative Update • Mar 21
REG1V: Upgrades And Dividend Flexibility Will Drive Future Upside Repricing
Analysts have nudged their price target for Revenio Group Oyj slightly lower to €23.50 from €26, reflecting updated views on valuation, while core assumptions around revenue growth, margins and P/E multiples remain broadly unchanged. Analyst Commentary Recent research points to a mixed but generally constructive view on Revenio Group Oyj, with some analysts trimming valuation assumptions while others take a more optimistic stance on the shares.Narrative Update • Mar 06
REG1V: Refined Discount Assumptions And Upgrades Will Drive Future Upside Repricing
Analysts have trimmed their price target for Revenio Group Oyj to €23.50 from €23.97, noting slightly lower assumed revenue growth and P/E multiples. This is partly balanced by marginally higher profit margin expectations and a small adjustment to the discount rate.Narrative Update • Feb 19
REG1V: Refined Discount Assumptions Will Support Future Upside Repricing
Analysts have adjusted their price target for Revenio Group Oyj from €26.25 to about €23.97, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bullish analysts have recently become more constructive on Revenio Group Oyj, which aligns with the updated price target and the refined assumptions used in the valuation work.Narrative Update • Feb 04
REG1V: Product Operating Model Shift Will Drive Future Upside Potential
Analysts have nudged their fair value estimate for Revenio Group Oyj lower from €27.70 to €26.25, citing slightly adjusted assumptions for revenue growth, profit margin, discount rate and future P/E multiples. What's in the News Chief Financial Officer and Leadership Team member Robin Pulkkinen has resigned to take a role outside the company and will remain with Revenio Group Oyj through his notice period, leaving no later than June 2026 (Key Developments).Narrative Update • Jan 21
REG1V: Product Operating Model Shift Will Support Future Upside Potential
Analysts have trimmed their price target for Revenio Group Oyj by €0.55 to €27.70, citing updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, which slightly adjust their overall valuation framework. What's in the News Chief Financial Officer and Leadership Team member Robin Pulkkinen has resigned to take a role outside Revenio Group, with his departure scheduled no later than June 2026, and the company starting the search for a new CFO immediately (Key Developments).Narrative Update • Jan 06
REG1V: Product Operating Model Will Support Long Term Upside Potential
Analysts have trimmed their price target for Revenio Group Oyj by €0.50 to €28.25, citing slightly softer assumptions for revenue growth and profit margins, partly offset by a modestly higher assumed future P/E multiple. What's in the News Chief Financial Officer and Leadership Team member Robin Pulkkinen has resigned to take a role outside the company.Narrative Update • Dec 15
REG1V: Product Operating Model Will Drive Stronger Customer Value In Future
Analysts have maintained their fair value estimate for Revenio Group Oyj at EUR 28.75, as only marginal adjustments to the discount rate, revenue growth, profit margin and future P E assumptions left their overall valuation view unchanged. What's in the News Revenio Group Oyj has decided to adopt a Product Operating Model to strengthen customer centricity and organizational agility (company announcement) Under the new model, teams, processes and systems will be organized around products so that customer value and business development drive daily activities (company announcement) The Product Operating Model is intended to support continuous and agile development in both product development and product management (company announcement) Valuation Changes Fair Value Estimate: unchanged at €28.75 per share, with no revision to the overall valuation view.Narrative Update • Nov 27
REG1V: Customer-Focused Operating Model Will Drive Long-Term Performance Upside
Analysts have maintained their fair value estimate for Revenio Group Oyj at €28.75, citing only minor adjustments to key assumptions and reaffirming confidence in the company’s long-term outlook. What's in the News Revenio Group Oyj is implementing a new Product Operating Model to increase customer centricity and agility by organizing work, processes, and teams around products (Client Announcements).Narrative Update • Nov 13
REG1V: Modestly Lower Margins and Revenue Will Support Stronger Long-Term Returns
Analysts have lowered their price target for Revenio Group Oyj from €29.20 to €28.75, citing more conservative estimates for revenue growth and profit margins. Valuation Changes The Fair Value Estimate has decreased slightly from €29.20 to €28.75.Analysis Article • Nov 03
Revenio Group Oyj Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next
Last week, you might have seen that Revenio Group Oyj ( HEL:REG1V ) released its quarterly result to the market. The...Analysis Article • May 14
Revenio Group Oyj's (HEL:REG1V) 25% Jump Shows Its Popularity With Investors
Those holding Revenio Group Oyj ( HEL:REG1V ) shares would be relieved that the share price has rebounded 25% in the...Analysis Article • May 02
Earnings Miss: Revenio Group Oyj Missed EPS By 5.8% And Analysts Are Revising Their Forecasts
It's been a pretty great week for Revenio Group Oyj ( HEL:REG1V ) shareholders, with its shares surging 14% to €27.50...Analysis Article • Apr 23
Is Revenio Group Oyj (HEL:REG1V) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Feb 16
Here's What Analysts Are Forecasting For Revenio Group Oyj (HEL:REG1V) After Its Annual Results
Revenio Group Oyj ( HEL:REG1V ) shareholders are probably feeling a little disappointed, since its shares fell 6.9% to...Analysis Article • Jan 21
What Does Revenio Group Oyj's (HEL:REG1V) Share Price Indicate?
While Revenio Group Oyj ( HEL:REG1V ) might not have the largest market cap around , it saw a decent share price growth...
New Narrative • Jan 16
New Medical Devices And AI Integration Will Fuel Future Success In Medical Markets
Expansion into the Chinese market and successful product launches are set to drive significant future revenue growth across diverse markets.Analysis Article • Oct 12
Shareholders Should Be Pleased With Revenio Group Oyj's (HEL:REG1V) Price
When close to half the companies in Finland have price-to-earnings ratios (or "P/E's") below 18x, you may consider...Analysis Article • Aug 11
Investors Shouldn't Overlook Revenio Group Oyj's (HEL:REG1V) Impressive Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...Analysis Article • Jun 20
Calculating The Intrinsic Value Of Revenio Group Oyj (HEL:REG1V)
Key Insights The projected fair value for Revenio Group Oyj is €30.29 based on 2 Stage Free Cash Flow to Equity With...Analysis Article • May 21
What Does Revenio Group Oyj's (HEL:REG1V) Share Price Indicate?
While Revenio Group Oyj ( HEL:REG1V ) might not have the largest market cap around , it saw a significant share price...Analysis Article • Apr 27
Revenio Group Oyj Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Investors in Revenio Group Oyj ( HEL:REG1V ) had a good week, as its shares rose 2.3% to close at €25.22 following the...Analysis Article • Mar 29
It's Unlikely That The CEO Of Revenio Group Oyj (HEL:REG1V) Will See A Huge Pay Rise This Year
Key Insights Revenio Group Oyj's Annual General Meeting to take place on 4th of April Salary of €254.8k is part of CEO...Analysis Article • Feb 18
€27.88 - That's What Analysts Think Revenio Group Oyj (HEL:REG1V) Is Worth After These Results
Investors in Revenio Group Oyj ( HEL:REG1V ) had a good week, as its shares rose 3.1% to close at €26.90 following the...Analysis Article • Feb 16
Is Revenio Group Oyj (HEL:REG1V) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Dec 15
Why Revenio Group Oyj (HEL:REG1V) Could Be Worth Watching
Revenio Group Oyj ( HEL:REG1V ), might not be a large cap stock, but it received a lot of attention from a substantial...Analysis Article • Aug 03
Revenio Group Oyj (HEL:REG1V) Seems To Use Debt Rather Sparingly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Jun 13
Is Revenio Group Oyj (HEL:REG1V) Potentially Undervalued?
Revenio Group Oyj ( HEL:REG1V ), might not be a large cap stock, but it received a lot of attention from a substantial...Analysis Article • May 09
If EPS Growth Is Important To You, Revenio Group Oyj (HEL:REG1V) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Apr 11
Revenio Group Oyj (HEL:REG1V) Has A Rock Solid Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Shareholder Returns
| REG1V | FI Medical Equipment | FI Market | |
|---|---|---|---|
| 7D | -0.3% | 0.6% | -2.2% |
| 1Y | -54.1% | -45.2% | 29.0% |
Return vs Industry: REG1V underperformed the Finnish Medical Equipment industry which returned -45.2% over the past year.
Return vs Market: REG1V underperformed the Finnish Market which returned 29% over the past year.
Price Volatility
| REG1V volatility | |
|---|---|
| REG1V Average Weekly Movement | 5.7% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in FI Market | 8.1% |
| 10% least volatile stocks in FI Market | 3.2% |
Stable Share Price: REG1V has not had significant price volatility in the past 3 months compared to the Finnish market.
Volatility Over Time: REG1V's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 246 | Jouni Toijala | www.reveniogroup.fi |
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images.
Revenio Group Oyj Fundamentals Summary
| REG1V fundamental statistics | |
|---|---|
| Market cap | €333.10m |
| Earnings (TTM) | €15.71m |
| Revenue (TTM) | €111.05m |
21.2x
P/E Ratio3.0x
P/S RatioIs REG1V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REG1V income statement (TTM) | |
|---|---|
| Revenue | €111.05m |
| Cost of Revenue | €33.38m |
| Gross Profit | €77.67m |
| Other Expenses | €61.96m |
| Earnings | €15.71m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Sep 08, 2026
| Earnings per share (EPS) | 0.59 |
| Gross Margin | 69.94% |
| Net Profit Margin | 14.15% |
| Debt/Equity Ratio | 5.1% |
How did REG1V perform over the long term?
See historical performance and comparisonDividends
3.5%
Current Dividend Yield75%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/20 09:17 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Revenio Group Oyj is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pia Rosqvist-Heinsalmi | Carnegie Investment Bank AB |
| Daniel Lepisto | Danske Bank |
| Pia Rosqvist-Heinsalmi | DNB Carnegie |